Intellia Therapeutics Inc Stock
Heavy losses for Intellia Therapeutics Inc today as the stock fell by -€0.330 (-3.430%).
Currently there is a rather positive sentiment for Intellia Therapeutics Inc with 26 Buy predictions and 5 Sell predictions.
With a target price of 24 € there is potential for a 159.18% increase which would mean more than doubling the current price of 9.26 € for Intellia Therapeutics Inc.
Our community identified positive and negative aspects for Intellia Therapeutics Inc stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Intellia Therapeutics Inc stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | -3.430% | -1.907% | -37.517% | -9.171% | 18.627% | -75.948% | -92.254% |
| Chromadex Corp | 2.880% | 2.143% | 3.623% | -65.122% | -48.000% | 90.667% | -60.822% |
| Cardio3 Biosciences S.A. | -0.860% | 3.125% | 20.313% | -37.903% | 71.111% | -53.144% | -93.135% |
| Polynovo Ltd | 3.390% | 0.000% | -4.314% | -28.759% | -28.235% | -49.167% | -64.638% |
Comments
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $49.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its price target lowered by HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
News
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
An exciting new CRISPR-based tool is making waves in the scientific literature this spring. Because the new technology destroys targeted diseased cells outright rather than editing their genetic
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
Intellia Therapeutics (NASDAQ: NTLA) has been on fire this year. Shares of the clinical-stage biotech have climbed an impressive 83% to date. However, Wall Street remains bullish on the company
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Choosing between Intellia Therapeutics (NASDAQ:NTLA) and Omeros (NASDAQ:OMER) in 2026 requires balancing the explosive potential of gene editing against the steady rollout of newly approved orphan